The CHS/Pfizer Care until Cure Research Program
The CHS/Pfizer Care until Cure Research Program funds Canadian research to advance treatment and care for inherited bleeding disorders, led by the Canadian Hemophilia Society.
Funder: Canadian Hemophilia Society
Due Dates: November 28, 2026 (Annual application deadline)
Funding Amounts: Up to $75,000/year, max $150,000 over 2–3 years per project
Summary: Supports Canadian research to improve care, treatment, and outcomes for individuals with hemophilia, inherited bleeding disorders, and related conditions.
Key Information: Applicants must be Canadian citizens/permanent residents affiliated with a Canadian university or not-for-profit health organization.
Description
The CHS/Pfizer Care until Cure Research Program, a partnership between the Canadian Hemophilia Society and Pfizer Canada, funds innovative research projects that address the medical and psychosocial aspects of bleeding disorders. The program aims to advance clinical care, treatment strategies, and outcome evaluation for Canadians affected by hemophilia, von Willebrand disease, other inherited bleeding disorders, related conditions (e.g., HIV or hepatitis C), and carriers of bleeding disorders. Supported projects may focus on epidemiology, real-world data, personalized treatment, clinical monitoring, gene therapy, TFPI/anti-TFPI therapies, antifibrinolytic therapy, and more. The program encourages proposals that foster evidence-based improvements in quality of life and care for people living with bleeding disorders in Canada.
